ResMed (NYSE: RMD) has outperformed the market over the past 10 years by 2.9% on an annualized basis producing an average annual return of 16.12%. Currently, ResMed has a market capitalization of ...

Jan 29 (Reuters) - Medical device maker ResMed (RMD.N), opens new tab on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep ...

Singaporean provider of modular and prefabricated data center infrastructure EPG has completed its Series B financing, raising nearly US$100 million. The round was co-led by international investment ...

ResMed posted a 9% revenue increase and an 11% rise in net income for the September quarter, driven by increased demand for sleep treatment products. The company demonstrated strong growth in various ...

As shown in the following overview of ResMed’s global leadership position: Quarterly Performance Highlights ResMed delivered strong financial results for Q4 FY2025, with revenue reaching $1.35 billion ...

Fractus, a company specializing in geometry-based antenna technology and IP licensing, has filed a patent infringement suit against respiratory leader ResMed. The complaint was filed in the United ...

However, I’m also keenly aware that not everyone can afford a $1,000 smartphone. For many people, the premium features of a “Pro” moniker, especially the fancy camera tricks, are overkill for their ...

ResMed, an ASX healthcare leader, is well-positioned to capitalise on the growing demand for sleep apnoea treatment and digital health solutions, offering potential long-term rewards. The company's ...

I’m one of PCMag’s mobile writers. That means I check out phones, hotspots, and mobile networks. Technology has been my passion and hobby since I was a child. I’ve covered tech professionally for over ...

Resmed has beaten full-year earnings and revenue forecasts on the back of strong global sales of its devices to treat sleep apnoea, shrugging off the threat of US President Donald Trump’s trade ...

Revenue: $1.35 billion, a 10% increase year-over-year. Gross Margin: 61.4%, an expansion of 230 basis points year-over-year. Free Cash Flow: $1.7 billion for fiscal year 2025. Net Income: Increased by ...

Resmed announced that it will release its financial and operational results for the fourth quarter of fiscal year 2025 on July 31, 2025, after the market closes. Following the release, management will ...